Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATNFWNASDAQ:SXTPWOTCMKTS:TRSBFOTCMKTS:WXXWY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNFW180 Life Sciences$0.01+7.5%$0.01$0.00▼$0.04N/AN/A96,920 shs41,006 shsSXTPW60 Degrees Pharmaceuticals$0.06+11.5%$0.06$0.01▼$0.10N/AN/A16,698 shs1,818 shsTRSBF3SBio$3.25+12.1%$2.08$2.22▼$3.35N/AN/A781 shs875 shsWXXWYWuXi Biologics (Cayman)$6.40-1.8%$6.19$2.58▼$7.30N/AN/A44,861 shs3,017 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNFW180 Life Sciences+7.50%+3.61%+7.50%+22.86%-14.00%SXTPW60 Degrees Pharmaceuticals0.00%+11.46%-8.18%+147.37%-19.54%TRSBF3SBio0.00%+10.17%+25.00%+292.56%+323.62%WXXWYWuXi Biologics (Cayman)+2.68%+1.72%+5.84%-3.55%+123.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNFW180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ASXTPW60 Degrees PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATRSBF3SBioN/AN/AN/AN/AN/AN/AN/AN/AWXXWYWuXi Biologics (Cayman)N/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNFW180 Life Sciences 0.00N/AN/AN/ASXTPW60 Degrees Pharmaceuticals 0.00N/AN/AN/ATRSBF3SBio 0.00N/AN/AN/AWXXWYWuXi Biologics (Cayman) 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNFW180 Life SciencesN/AN/AN/AN/AN/AN/ASXTPW60 Degrees Pharmaceuticals$665.45KN/AN/AN/AN/AN/ATRSBF3SBioN/AN/AN/AN/AN/AN/AWXXWYWuXi Biologics (Cayman)N/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNFW180 Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/ASXTPW60 Degrees PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/ATRSBF3SBioN/AN/A0.00∞N/AN/AN/AN/A8/20/2025 (Estimated)WXXWYWuXi Biologics (Cayman)N/AN/A0.00∞N/AN/AN/AN/A8/19/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNFW180 Life SciencesN/AN/AN/AN/AN/ASXTPW60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ATRSBF3SBioN/AN/AN/AN/AN/AWXXWYWuXi Biologics (Cayman)N/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNFW180 Life SciencesN/ASXTPW60 Degrees PharmaceuticalsN/ATRSBF3SBioN/AWXXWYWuXi Biologics (Cayman)N/AInsider OwnershipCompanyInsider OwnershipATNFW180 Life SciencesN/ASXTPW60 Degrees PharmaceuticalsN/ATRSBF3SBioN/AWXXWYWuXi Biologics (Cayman)N/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNFW180 Life Sciences7N/AN/ANot OptionableSXTPW60 Degrees Pharmaceuticals2N/AN/ANot OptionableTRSBF3SBio5,411N/AN/ANot OptionableWXXWYWuXi Biologics (Cayman)12,435N/AN/ANot OptionableWXXWY, ATNFW, TRSBF, and SXTPW HeadlinesRecent News About These CompaniesWuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mLJune 30 at 7:00 AM | prnewswire.comWXXWY WuXi Biologics (Cayman) Inc. - Seeking AlphaJune 28, 2025 | seekingalpha.comWuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in ChengduJune 9, 2025 | prnewswire.comWuXi Biologics: Eyes On Long-Term Risks And Near-Term Outlook (Rating Downgrade)May 18, 2025 | seekingalpha.comWuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPAMay 16, 2025 | prnewswire.comDriving Impact Through Responsibility: WuXi Biologics Releases 2024 Sustainability ReportApril 29, 2025 | prnewswire.comWuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive YearApril 22, 2025 | prnewswire.comWuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou SiteApril 18, 2025 | prnewswire.comWuXi Biologics Wins Five Asia-Pacific Biopharma Excellence AwardsApril 14, 2025 | prnewswire.comWuXi Biologics Posts Strong 2024 Results Forecasts Rapid Growth in 2025March 26, 2025 | msn.comWuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025March 25, 2025 | prnewswire.comWuXi Biologics Receives CDMO Leadership Awards for Eighth Consecutive YearMarch 23, 2025 | prnewswire.comWuXi Biologics Named to CDP Water Security "A List" for Second Consecutive YearMarch 20, 2025 | prnewswire.comWuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA ProductionMarch 3, 2025 | prnewswire.comWuXi Biologics Again Passed GMP Inspection by Japan PMDAFebruary 26, 2025 | prnewswire.comWuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive YearFebruary 18, 2025 | prnewswire.comWuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive YearFebruary 10, 2025 | prnewswire.comWuXi Biologics: Buy Rating Supported by Strong Performance, Strategic Growth, and Increased Target PriceJanuary 18, 2025 | markets.businessinsider.comWuxi Biologics upgraded to Overweight from Neutral at JPMorganJanuary 7, 2025 | markets.businessinsider.comWuXi Bio to Sell Vaccine Facility to Merck for $500 MillionJanuary 6, 2025 | bloomberg.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeWXXWY, ATNFW, TRSBF, and SXTPW Company Descriptions180 Life Sciences NASDAQ:ATNFW$0.0086 +0.00 (+7.50%) As of 07/1/2025 01:40 PM Eastern180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.60 Degrees Pharmaceuticals NASDAQ:SXTPW$0.06 +0.01 (+11.46%) As of 06/27/202560 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.3SBio OTCMKTS:TRSBF$3.25 +0.35 (+12.07%) As of 06/30/2025 02:50 PM Eastern3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium. In addition, the company provides MN709 Minoxidil Foam and Nalfuraphine hydrochloride tablets. Further, it provides trading, project management and consultation, technology, sports, financial, investment advisory, as well as manufactures medical devices; and offers agricultural services. The company has collaboration agreements with companies, such as Toray. 3SBio Inc. was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.WuXi Biologics (Cayman) OTCMKTS:WXXWY$6.40 -0.12 (-1.84%) As of 10:33 AM EasternWuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and engages in investment and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates. The company was incorporated in 2014 and is headquartered in Wuxi, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock 3 Utility Stocks That Combine Income and Stability 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Why Realty Income’s 5.59% Yield Makes It a Must-Buy REIT Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
